Adults Vaccines Market Size, Share & Industry Analysis, By Type (Recombinant/Conjugate/Subunit, Inactivated, mRNA, Viral Vector, Live Attenuated, Toxoid, and Others), By Route of Administration (Parenteral and Oral), By Disease Indication (Viral Diseases {Hepatitis, Influenza, Human Papillomavirus, Herpes Zoster, and Others} and Bacterial Diseases {Meningococcal Disease, Pneumococcal Disease, Diphtheria/Tetanus/Pertussis, and Others}), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, and Others), and Regional Forecast, 2025-2032

Last Updated: December 08, 2025 | Format: PDF | Report ID: FBI113663

We will customize the report to meet your research goals, helping you gain a competitive edge, and make informed decisions.

Schedule a 30 minutes session to understand our consulting capabilities – SCHEDULE NOW

Table of Content

Introduction
1. Research Scope
2. Market Segmentation
3. Research Methodology
4. Definitions and Assumptions
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
4. Market Trends
Key Insights
1. Incidence/Prevalence of Key Diseases, By Key Countries/Regions, 2024
2. Technological Advancements in the Adults Vaccines
3. New Product Launches, By Key Players
4. Pipeline Analysis, By Key Players
5. Key Industry Developments Such as Mergers, Acquisitions, and Partnerships
Global Adults Vaccines Market Analysis, Insights and Forecast, 2019-2032
1. Market Analysis, Insights and Forecast – By Type
  1. Recombinant/Conjugate/Subunit
  2. Inactivated
  3. mRNA
  4. Viral Vector
  5. Live Attenuated
  6. Toxoid
  7. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Parenteral
  2. Oral
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Viral Diseases
    1. Hepatitis
    2. Influenza
    3. Human Papillomavirus
    4. Herpes Zoster
    5. Others
  2. Bacterial Diseases
    1. Meningococcal Disease
    2. Pneumococcal Disease
    3. Diphtheria/Tetanus/Pertussis
    4. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital & Retail Pharmacies
  2. Government Suppliers
  3. Others
5. Market Analysis, Insights and Forecast – By Region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Latin America
  5. Middle East & Africa
North America Adults Vaccines Market Analysis, Insights and Forecast, 2019-2032
1. Market Analysis, Insights and Forecast – By Type
  1. Recombinant/Conjugate/Subunit
  2. Inactivated
  3. mRNA
  4. Viral Vector
  5. Live Attenuated
  6. Toxoid
  7. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Parenteral
  2. Oral
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Viral Diseases
    1. Hepatitis
    2. Influenza
    3. Human Papillomavirus
    4. Herpes Zoster
    5. Others
  2. Bacterial Diseases
    1. Meningococcal Disease
    2. Pneumococcal Disease
    3. Diphtheria/Tetanus/Pertussis
    4. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital & Retail Pharmacies
  2. Government Suppliers
  3. Others
5. Market Analysis, Insights and Forecast – By Country
  1. U.S.
  2. Canada
Europe Adults Vaccines Market Analysis, Insights and Forecast, 2019-2032
1. Market Analysis, Insights and Forecast – By Type
  1. Recombinant/Conjugate/Subunit
  2. Inactivated
  3. mRNA
  4. Viral Vector
  5. Live Attenuated
  6. Toxoid
  7. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Parenteral
  2. Oral
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Viral Diseases
    1. Hepatitis
    2. Influenza
    3. Human Papillomavirus
    4. Herpes Zoster
    5. Others
  2. Bacterial Diseases
    1. Meningococcal Disease
    2. Pneumococcal Disease
    3. Diphtheria/Tetanus/Pertussis
    4. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital & Retail Pharmacies
  2. Government Suppliers
  3. Others
5. Market Analysis, Insights and Forecast – By Country/Sub-region
  1. U.K.
  2. Germany
  3. France
  4. Spain
  5. Italy
  6. Scandinavia
  7. Rest of Europe
Asia Pacific Adults Vaccines Market Analysis, Insights and Forecast, 2019-2032
1. Market Analysis, Insights and Forecast – By Type
  1. Recombinant/Conjugate/Subunit
  2. Inactivated
  3. mRNA
  4. Viral Vector
  5. Live Attenuated
  6. Toxoid
  7. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Parenteral
  2. Oral
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Viral Diseases
    1. Hepatitis
    2. Influenza
    3. Human Papillomavirus
    4. Herpes Zoster
    5. Others
  2. Bacterial Diseases
    1. Meningococcal Disease
    2. Pneumococcal Disease
    3. Diphtheria/Tetanus/Pertussis
    4. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital & Retail Pharmacies
  2. Government Suppliers
  3. Others
5. Market Analysis, Insights and Forecast – By Country/Sub-region
  1. Japan
  2. China
  3. India
  4. Australia
  5. Southeast Asia
  6. Rest of Asia Pacific
Latin America Adults Vaccines Market Analysis, Insights and Forecast, 2019-2032
1. Market Analysis, Insights and Forecast – By Type
  1. Recombinant/Conjugate/Subunit
  2. Inactivated
  3. mRNA
  4. Viral Vector
  5. Live Attenuated
  6. Toxoid
  7. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Parenteral
  2. Oral
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Viral Diseases
    1. Hepatitis
    2. Influenza
    3. Human Papillomavirus
    4. Herpes Zoster
    5. Others
  2. Bacterial Diseases
    1. Meningococcal Disease
    2. Pneumococcal Disease
    3. Diphtheria/Tetanus/Pertussis
    4. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital & Retail Pharmacies
  2. Government Suppliers
  3. Others
5. Market Analysis, Insights and Forecast – By Country/Sub-region
  1. Brazil
  2. Mexico
  3. Rest of Latin America
Middle East & Africa Adults Vaccines Market Analysis, Insights and Forecast, 2019-2032
1. Market Analysis, Insights and Forecast – By Type
  1. Recombinant/Conjugate/Subunit
  2. Inactivated
  3. mRNA
  4. Viral Vector
  5. Live Attenuated
  6. Toxoid
  7. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Parenteral
  2. Oral
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Viral Diseases
    1. Hepatitis
    2. Influenza
    3. Human Papillomavirus
    4. Herpes Zoster
    5. Others
  2. Bacterial Diseases
    1. Meningococcal Disease
    2. Pneumococcal Disease
    3. Diphtheria/Tetanus/Pertussis
    4. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital & Retail Pharmacies
  2. Government Suppliers
  3. Others
5. Market Analysis, Insights and Forecast – By Country/Sub-region
  1. GCC
  2. South Africa
  3. Rest of Middle East & Africa
Competitive Analysis
1. Global Market Share Analysis (2024)
2. Company Profiles
  1. Bavarian Nordic
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  2. GSK plc
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  3. EMERGENT
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  4. Merck & Co., Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  5. Inovio Pharmaceuticals, Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  6. Pfizer Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  7. Sanofi
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  8. CSL
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  9. AstraZeneca
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)

Introduction
1. Research Scope
2. Market Segmentation
3. Research Methodology
4. Definitions and Assumptions
Executive Summary
Market Dynamics
1. Market Drivers
2. Market Restraints
3. Market Opportunities
4. Market Trends
Key Insights
1. Incidence/Prevalence of Key Diseases, By Key Countries/Regions, 2024
2. Technological Advancements in the Adults Vaccines
3. New Product Launches, By Key Players
4. Pipeline Analysis, By Key Players
5. Key Industry Developments Such as Mergers, Acquisitions, and Partnerships
Global Adults Vaccines Market Analysis, Insights and Forecast, 2019-2032
1. Market Analysis, Insights and Forecast – By Type
  1. Recombinant/Conjugate/Subunit
  2. Inactivated
  3. mRNA
  4. Viral Vector
  5. Live Attenuated
  6. Toxoid
  7. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Parenteral
  2. Oral
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Viral Diseases
    1. Hepatitis
    2. Influenza
    3. Human Papillomavirus
    4. Herpes Zoster
    5. Others
  2. Bacterial Diseases
    1. Meningococcal Disease
    2. Pneumococcal Disease
    3. Diphtheria/Tetanus/Pertussis
    4. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital & Retail Pharmacies
  2. Government Suppliers
  3. Others
5. Market Analysis, Insights and Forecast – By Region
  1. North America
  2. Europe
  3. Asia Pacific
  4. Latin America
  5. Middle East & Africa
North America Adults Vaccines Market Analysis, Insights and Forecast, 2019-2032
1. Market Analysis, Insights and Forecast – By Type
  1. Recombinant/Conjugate/Subunit
  2. Inactivated
  3. mRNA
  4. Viral Vector
  5. Live Attenuated
  6. Toxoid
  7. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Parenteral
  2. Oral
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Viral Diseases
    1. Hepatitis
    2. Influenza
    3. Human Papillomavirus
    4. Herpes Zoster
    5. Others
  2. Bacterial Diseases
    1. Meningococcal Disease
    2. Pneumococcal Disease
    3. Diphtheria/Tetanus/Pertussis
    4. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital & Retail Pharmacies
  2. Government Suppliers
  3. Others
5. Market Analysis, Insights and Forecast – By Country
  1. U.S.
  2. Canada
Europe Adults Vaccines Market Analysis, Insights and Forecast, 2019-2032
1. Market Analysis, Insights and Forecast – By Type
  1. Recombinant/Conjugate/Subunit
  2. Inactivated
  3. mRNA
  4. Viral Vector
  5. Live Attenuated
  6. Toxoid
  7. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Parenteral
  2. Oral
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Viral Diseases
    1. Hepatitis
    2. Influenza
    3. Human Papillomavirus
    4. Herpes Zoster
    5. Others
  2. Bacterial Diseases
    1. Meningococcal Disease
    2. Pneumococcal Disease
    3. Diphtheria/Tetanus/Pertussis
    4. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital & Retail Pharmacies
  2. Government Suppliers
  3. Others
5. Market Analysis, Insights and Forecast – By Country/Sub-region
  1. U.K.
  2. Germany
  3. France
  4. Spain
  5. Italy
  6. Scandinavia
  7. Rest of Europe
Asia Pacific Adults Vaccines Market Analysis, Insights and Forecast, 2019-2032
1. Market Analysis, Insights and Forecast – By Type
  1. Recombinant/Conjugate/Subunit
  2. Inactivated
  3. mRNA
  4. Viral Vector
  5. Live Attenuated
  6. Toxoid
  7. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Parenteral
  2. Oral
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Viral Diseases
    1. Hepatitis
    2. Influenza
    3. Human Papillomavirus
    4. Herpes Zoster
    5. Others
  2. Bacterial Diseases
    1. Meningococcal Disease
    2. Pneumococcal Disease
    3. Diphtheria/Tetanus/Pertussis
    4. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital & Retail Pharmacies
  2. Government Suppliers
  3. Others
5. Market Analysis, Insights and Forecast – By Country/Sub-region
  1. Japan
  2. China
  3. India
  4. Australia
  5. Southeast Asia
  6. Rest of Asia Pacific
Latin America Adults Vaccines Market Analysis, Insights and Forecast, 2019-2032
1. Market Analysis, Insights and Forecast – By Type
  1. Recombinant/Conjugate/Subunit
  2. Inactivated
  3. mRNA
  4. Viral Vector
  5. Live Attenuated
  6. Toxoid
  7. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Parenteral
  2. Oral
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Viral Diseases
    1. Hepatitis
    2. Influenza
    3. Human Papillomavirus
    4. Herpes Zoster
    5. Others
  2. Bacterial Diseases
    1. Meningococcal Disease
    2. Pneumococcal Disease
    3. Diphtheria/Tetanus/Pertussis
    4. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital & Retail Pharmacies
  2. Government Suppliers
  3. Others
5. Market Analysis, Insights and Forecast – By Country/Sub-region
  1. Brazil
  2. Mexico
  3. Rest of Latin America
Middle East & Africa Adults Vaccines Market Analysis, Insights and Forecast, 2019-2032
1. Market Analysis, Insights and Forecast – By Type
  1. Recombinant/Conjugate/Subunit
  2. Inactivated
  3. mRNA
  4. Viral Vector
  5. Live Attenuated
  6. Toxoid
  7. Others
2. Market Analysis, Insights and Forecast – By Route of Administration
  1. Parenteral
  2. Oral
3. Market Analysis, Insights and Forecast – By Disease Indication
  1. Viral Diseases
    1. Hepatitis
    2. Influenza
    3. Human Papillomavirus
    4. Herpes Zoster
    5. Others
  2. Bacterial Diseases
    1. Meningococcal Disease
    2. Pneumococcal Disease
    3. Diphtheria/Tetanus/Pertussis
    4. Others
4. Market Analysis, Insights and Forecast – By Distribution Channel
  1. Hospital & Retail Pharmacies
  2. Government Suppliers
  3. Others
5. Market Analysis, Insights and Forecast – By Country/Sub-region
  1. GCC
  2. South Africa
  3. Rest of Middle East & Africa
Competitive Analysis
1. Global Market Share Analysis (2024)
2. Company Profiles
  1. Bavarian Nordic
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  2. GSK plc
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  3. EMERGENT
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  4. Merck & Co., Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  5. Inovio Pharmaceuticals, Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  6. Pfizer Inc.
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  7. Sanofi
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  8. CSL
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)
  9. AstraZeneca
    1. Overview
    2. Products
    3. SWOT Analysis
    4. Recent Developments
    5. Strategies
    6. Financials (Based on Availability)

Read Less

List of Figures

Figure 1: Global Adults Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2024 & 2032

Figure 2: Global Adults Vaccines Market Value Share (%), by Type, 2024 & 2032

Figure 3: Global Adults Vaccines Market Value Share (%), by Route of Administration, 2024 & 2032

Figure 4: Global Adults Vaccines Market Value Share (%), by Disease Indication, 2024 & 2034

Figure 5: Global Adults Vaccines Market Value Share (%), by Distribution Channel, 2024 & 2032

Figure 6: Global Adults Vaccines Market Value Share (%), by Region, 2024 & 2032

Figure 7: North America Adults Vaccines Market Value (USD billion), by Type, 2024 & 2032

Figure 8: North America Adults Vaccines Market Value Share (%), by Type, 2024

Figure 9: North America Adults Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032

Figure 10: North America Adults Vaccines Market Value Share (%), by Route of Administration, 2024

Figure 11: North America Adults Vaccines Market Value (USD billion), by Disease Indication, 2024 & 2032

Figure 12: North America Adults Vaccines Market Value Share (%), by Disease Indication, 2024

Figure 13: North America Adults Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032

Figure 14: North America Adults Vaccines Market Value Share (%), by Distribution Channel, 2024

Figure 15: North America Adults Vaccines Market Value (USD billion), By Country, 2024 & 2032

Figure 16: North America Adults Vaccines Market Value Share (%), By Country, 2024

Figure 17: Europe Adults Vaccines Market Value (USD billion), by Type, 2024 & 2032

Figure 18: Europe Adults Vaccines Market Value Share (%), by Type, 2024

Figure 19: Europe Adults Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032

Figure 20: Europe Adults Vaccines Market Value Share (%), by Route of Administration, 2024

Figure 21: Europe Adults Vaccines Market Value (USD billion), by Disease Indication, 2024 & 2032

Figure 22: Europe Adults Vaccines Market Value Share (%), by Disease Indication, 2024

Figure 23: Europe Adults Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032

Figure 24: Europe Adults Vaccines Market Value Share (%), by Distribution Channel, 2024

Figure 25: Europe Adults Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032

Figure 26: Europe Adults Vaccines Market Value Share (%), By Country/ Sub-region, 2024

Figure 27: Asia Pacific Adults Vaccines Market Value (USD billion), by Type, 2024 & 2032

Figure 28: Asia Pacific Adults Vaccines Market Value Share (%), by Type, 2024

Figure 29: Asia Pacific Adults Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032

Figure 30: Asia Pacific Adults Vaccines Market Value Share (%), by Route of Administration, 2024

Figure 31: Asia Pacific Adults Vaccines Market Value (USD billion), by Disease Indication, 2024 & 2032

Figure 32: Asia Pacific Adults Vaccines Market Value Share (%), by Disease Indication, 2024

Figure 33: Asia Pacific Adults Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032

Figure 34: Asia Pacific Adults Vaccines Market Value Share (%), by Distribution Channel, 2024

Figure 35: Asia Pacific Adults Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032

Figure 36: Asia Pacific Adults Vaccines Market Value Share (%), By Country/ Sub-region, 2024

Figure 37: Latin America Adults Vaccines Market Value (USD billion), by Type, 2024 & 2032

Figure 38: Latin America Adults Vaccines Market Value Share (%), by Type, 2024

Figure 39: Latin America Adults Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032

Figure 40: Latin America Adults Vaccines Market Value Share (%), by Route of Administration, 2024

Figure 41: Latin America Adults Vaccines Market Value (USD billion), by Disease Indication, 2024 & 2032

Figure 42: Latin America Adults Vaccines Market Value Share (%), by Disease Indication, 2024

Figure 43: Latin America Adults Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032

Figure 44: Latin America Adults Vaccines Market Value Share (%), by Distribution Channel, 2024

Figure 45: Latin America Adults Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032

Figure 46: Latin America Adults Vaccines Market Value Share (%), By Country/ Sub-region, 2024

Figure 47: Middle East & Africa Adults Vaccines Market Value (USD billion), by Type, 2024 & 2032

Figure 48: Middle East & Africa Adults Vaccines Market Value Share (%), by Type, 2024

Figure 49: Middle East & Africa Adults Vaccines Market Value (USD billion), by Route of Administration, 2024 & 2032

Figure 50: Middle East & Africa Adults Vaccines Market Value Share (%), by Route of Administration, 2024

Figure 51: Middle East & Africa Adults Vaccines Market Value (USD billion), by Disease Indication, 2024 & 2032

Figure 52: Middle East & Africa Adults Vaccines Market Value Share (%), by Disease Indication, 2024

Figure 53: Middle East & Africa Adults Vaccines Market Value (USD billion), by Distribution Channel, 2024 & 2032

Figure 54: Middle East & Africa Adults Vaccines Market Value Share (%), by Distribution Channel, 2024

Figure 55: Middle East & Africa Adults Vaccines Market Value (USD billion), By Country/ Sub-region, 2024 & 2032

Figure 56: Middle East & Africa Adults Vaccines Market Value Share (%), By Country/ Sub-region, 2024

Figure 57: Global Adults Vaccines Market Share (%), By Company, 2024

List of Tables

Table 1: Global Adults Vaccines Market Revenue (USD billion) Forecast, by Type, 2019–2032

Table 2: Global Adults Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019–2032

Table 3: Global Adults Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2019–2034

Table 4: Global Adults Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2019–2034

Table 5: Global Adults Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2019–2034

Table 6: Global Adults Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019–2032

Table 7: Global Adults Vaccines Market Revenue (USD billion) Forecast, by Region, 2019-2032

Table 8: North America Adults Vaccines Market Revenue (USD billion) Forecast, by Type, 2019–2032

Table 9: North America Adults Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019–2032

Table 10: North America Adults Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2019–2032

Table 11: North America Adults Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2019–2034

Table 12: North America Adults Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2019–2034

Table 13: North America Adults Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019–2032

Table 14: North America Adults Vaccines Market Revenue (USD billion) Forecast, By Country, 2019-2032

Table 15: Europe Adults Vaccines Market Revenue (USD billion) Forecast, by Type, 2019–2032

Table 16: Europe Adults Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019–2032

Table 17: Europe Adults Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2019–2032

Table 18: Europe Adults Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2019–2034

Table 19: Europe Adults Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2019–2034

Table 20: Europe Adults Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019–2032

Table 21: Europe Adults Vaccines Market Revenue (USD billion) Forecast, By Country/Sub-region, 2019-2032

Table 22: Asia Pacific Adults Vaccines Market Revenue (USD billion) Forecast, by Type, 2019–2032

Table 23: Asia Pacific Adults Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019–2032

Table 24: Asia Pacific Adults Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2019–2032

Table 25: Asia Pacific Adults Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2019–2034

Table 26: Asia Pacific Adults Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2019–2034

Table 27: Asia Pacific Adults Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019–2032

Table 28: Asia Pacific Adults Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

Table 29: Latin America Adults Vaccines Market Revenue (USD billion) Forecast, by Type, 2019–2032

Table 30: Latin America Adults Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019–2032

Table 31: Latin America Adults Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2019–2032

Table 32: Latin America Adults Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2019–2034

Table 33: Latin America Adults Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2019–2034

Table 34: Latin America Adults Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019–2032

Table 35: Latin America Adults Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

Table 36: Middle East & Africa Adults Vaccines Market Revenue (USD billion) Forecast, by Type, 2019–2032

Table 37: Middle East & Africa Adults Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2019–2032

Table 38: Middle East & Africa Adults Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2019–2032

Table 39: Middle East & Africa Adults Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2019–2034

Table 40: Middle East & Africa Adults Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2019–2034

Table 41: Middle East & Africa Adults Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2019–2032

Table 42: Middle East & Africa Adults Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2019-2032

STUDY PERIOD: 2019-2032
BASE YEAR: 2024
HISTORICAL DATA: 2019-2023
NO OF PAGES: 220

Buy Now

Download Free Sample

Security Code

Growth Advisory Services

Clients

Related Reports

Get In Touch With Us

US +1 833 909 2966 ( Toll Free )

UK +44 808 502 0280 ( Toll Free )

+91 744 740 1245 (APAC)
sales@fortunebusinessinsights.com